|
||||||||||||||||||||||||||||||||||||||||||||
![]()
CAS号:252917-06-9
|
英文名称:CHIR-99021 (CT99021)
分子式
C22H18Cl2N8
分子量
465
EINECS号
809-015-4
MDL
MFCD11846251
Smiles
InChIKey
乙二醇化学百科
基本信息
物化性质
安全信息
生产及用途
CHIR99021是一种氨基嘧啶衍生物,其抑制GSK3α和GSK3β的IC50值分别为10和6.7 nM。CHIR-99021 (CT99021)是一种GSK-3α和GSK-3β抑制剂, IC50分别为10 nM and 6.7 nM。CHIR99201对CDKs没有交叉反应性,对GSK-3β的选择性是对CDKs选择性的350倍。CHIR-99021 可作为Wnt/β-catenin的激活剂并诱导自噬。
CHIR-99021 inhibits human GSK-3β with K i values of 9.8 nM. CHIR-99021 is a small organic molecule that inhibits GSK3α and GSK3β by competing for their ATP-binding sites.In vitro kinase assays reveal that CHIR-99021 specifically inhibits GSK3β (IC 50 =~5 nM) and GSK3α (IC 50 =~10 nM), with little effect on other kinases. In the presence of CHIR-99021 the viability of the ES-D3 cells is reduced by 24.7% at 2.5 μM, 56.3% at 5 μM, 61.9% at 7.5 μM and 69.2% at 10 μM CHIR-99021 with an IC 50 of 4.9 μM.
In ZDF rats, a single oral dose of CHIR-99021 (16 mg/kg or 48 mg/kg) rapidly lowers plasma glucose, with a maximal reduction of nearly 150 mg/dl 3-4 h after administration. CHIR99021 (2 mg/kg) given once, 4 h before irradiation, significantly improves survival after 14.5 Gy abdominal irradiation (ABI). CHIR99021 treatment significantly blocks crypt apoptosis and accumulation of p-H2AX + cells, and improves crypt regeneration and villus height. CHIR99021 treatment increases Lgr5 + cell survival by blocking apoptosis, and effectively prevents the reduction of Olfm4, Lgr5 and CD44 as early as 4 h.
上下游产品
上游产品共计:0个
下游产品共计:0个
相关产品
|
||||||||||||||||||||||||||||||||||||||||||||